PDF   Print   View All
May 19, 2003
Hemispherx Reports Positive Independent Study Results of Alferon N in the Treatment of Pig Coronavirus (Animal Model of SARS)
Amsterdam Group proves Koch’s Postulates on Human Coronavirus (SARS)

Clinical Study Shows Significantly Greater Survival Rates of Treated Piglets in Natural Outbreaks

Low Dose Alferon N Effective within 4 days of Treatment

Philadelphia, PA, Monday, May 19, 2003: Philadelphia, PA, May 19, 2003 – Hemispherx Biopharma, Inc. (AMEX: HEB) reports the results of a “double-blinded” independent study conducted in a pig population suffering from the pig coronavirus, after therapeutic intervention with one of the Company’s lead Products, Alferon N. Newborn piglets, treated with Alferon N, even in low doses, had significantly greater survival rates than placebo-treated, control, piglets. Recent tests, May 14, 2003, at the Erasmus Medical Center, Amsterdam, confirm “the proof that a coronavirus is the primary cause of the disease” (human SARS) by fulfilling Koch’s Postulates thru the serial steps of coronavirus isolation (from man), reintroduction of virus and recreation of disease in macaque monkeys.

About SARS Models in Animals
Since human SARS apparently has its roots in animal coronavirus, the Company believes that the drug’s effect in the animal study may be relevant to potential human applicability. However, further independent investigation is required to evaluate safety and efficacy in humans. In man, mortality with SARS can exceed 50% in certain age groups.

About Alferon N
Alferon N (Interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. It is the only natural-source, multispecies alpha interferon currently sold in the U.S. for the treatment of condylomata HPV and is also approved for sale in certain other countries, notably including Hong Kong (Republic of China) and Singapore.

About the Clinical Study in Farm Animals
Transmissible coronavirus is a devastating disease in piglets, especially in high-density living facilities, and can result in high mortality, even approaching 100% mortality in piglets less than 14 days of age. The Study was conducted in a piglet population of 1740 animals in Texas, U.S.A., living under typical field/farm conditions. During a natural outbreak of Pig Coronavirus, groups of piglets were treated for 4 consecutive days with placebo or 1.0, 10.0 or 20.0 international units of Alferon N. Survival data were analyzed by age of treatment and dosage. All dosages of Alferon N improved survival rates (p<0.01) and certain groups (higher dosage) had very significantly greater (p<0.001) survival rate of 94.6% (p<0.001 means that the probability of the results being by chance alone is less than 1 in 1000). Thus, Alferon N therapy modulates the natural course of otherwise very high morbidity and mortality commonly seen with Pig Coronavirus infections. In contrast, vaccination of pigs still results in unacceptable high death rates, suggesting that natural alpha interferon, such as Alferon, may be a superior treatment approach to nature porcine coronavirus outbreaks.

Background to the Study
The independent clinical study in piglets was performed by researchers in Amarillo, Texas, A&M Diagnostic Laboratory, DeKalb Swine Breeders, Inc. and Department of Pathobiology, College of Veterinary Medicine at the Ohio State University. Alferon N was provided and the study was performed several years before the present SARS outbreak and knowledge that porcine or avian coronavirus may “jump” across animal species to man. Other studies have independently collaborated the antiviral benefit of human leukocyte interferon in lower animal species (1994-2003) on viruses other than porcine coronaviruses.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon and the experimental immunotherapeutics/antivirals Ampligen and Oragens. These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Hemispherx Biopharma, Inc., Investor Relations
Dianne Will
(518) 398-6222, Fax: (518) 398-6223

HEB's Web Site: www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including AmpligenÒ and Oragensä) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic AlferonÒ do not imply that the product will ever be specifically approved commercially for these other treatment indications. The Alferon® asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.